Patents by Inventor Matthias BARONE

Matthias BARONE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210332050
    Abstract: The present invention relates to chemical compounds which can be used in particular as structural mimetics of proline-rich peptides. The compounds of the present invention are capable of selectively inhibiting Ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of these compounds as pharmaceutical agents and the use of the pharmaceutical agents for the treatment of tumor diseases.
    Type: Application
    Filed: February 26, 2019
    Publication date: October 28, 2021
    Inventors: Ronald Kühne, Hans-Günther Schmalz, Stephan Dohmen, Matthias Barone, Matthias Müller, Slim Chiha, Dominik Albat
  • Patent number: 10344053
    Abstract: The present invention relates to chemical compounds that can in particular be used as structural mimetics of proline-rich peptides. The compounds of the present invention are capable of selectively inhibiting ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of said compounds as pharmaceutical agents and to the use of the pharmaceutical agents to treat tumor diseases. The chemical compounds of the present invention can significantly inhibit the chemotaxis and motility of invasive tumor cells and can therefore be used in the treatment and/or prevention of tumor metastases.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: July 9, 2019
    Assignees: FORSCHUNGSVERBUND BERLIN E.V., UNIVERSITÄT ZU KÖLN
    Inventors: Ronald Kühne, Hans-Günther Schmalz, Matthias Müller, Cedric Reuter, Arne Soicke, Robert Opitz, Matthias Barone, Hartmut Oschkinat
  • Publication number: 20170320910
    Abstract: The present invention relates to chemical compounds that can in particular be used as structural mimetics of proline-rich peptides. The compounds of the present invention are capable of selectively inhibiting ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of said compounds as pharmaceutical agents and to the use of the pharmaceutical agents to treat tumor diseases. The chemical compounds of the present invention can significantly inhibit the chemotaxis and motility of invasive tumor cells and can therefore be used in the treatment and/or prevention of tumor metastases.
    Type: Application
    Filed: December 11, 2015
    Publication date: November 9, 2017
    Inventors: Ronald KÜHNE, Hans-Günther SCHMALZ, Matthias MÜLLER, Cedric REUTER, Arne SOICKE, Robert OPITZ, Matthias BARONE, Hartmut OSCHKINAT